Citius Pharmaceuticals (CTXR) Assets Average (2011 - 2026)
Citius Pharmaceuticals' (CTXR) quarterly Assets Average came in at $136.5 million in Q1 2026, up 12.7% YoY from $121.1 million in Q1 2025, and up 0.59% on a QoQ basis from $135.7 million in Q4 2025.
Citius Pharmaceuticals (CTXR) Assets Average (2011 - 2026) Analysis & Trends
Citius Pharmaceuticals (CTXR) has 16 years of Assets Average data on file, last reported at $136.5 million in Q1 2026.
- Quarterly Assets Average rose 12.7% year-over-year to $136.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $136.5 million (up 12.7% YoY) and the FY2025 annual result came in at $123.8 million, up 12.41% from the prior year.
- Assets Average rose to $136.5 million in Q1 2026, from $135.7 million in the prior quarter.
- In the past five years, Assets Average ranged from a high of $136.5 million in Q1 2026 to a low of $93.9 million in Q2 2024.
- A 5-year average of $115.9 million and a median of $117.2 million in 2022 frame the typical range for Assets Average.
- The widest YoY moves for Assets Average: up 56.08% in 2022, down 19.38% in 2022.
- Tracing CTXR's Assets Average over 5 years: stood at $112.9 million in 2022, then declined by 10.94% to $100.5 million in 2023, then climbed by 18.08% to $118.7 million in 2024, then increased by 14.31% to $135.7 million in 2025, then rose by 0.59% to $136.5 million in 2026.
- The last three Assets Average figures came in at $136.5 million (Q1 2026), $135.7 million (Q4 2025), and $129.3 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 11.22 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 8.86 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 5.34 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 2.09 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 19.82 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 25.27 Bn |
| 10 | Citius Pharmaceuticals | 15.60 Mn | 15.60 Mn | 1.00 Mn | 137.40 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 136.47 Mn |
| Dec 31, 2025 | 135.66 Mn |
| Sep 30, 2025 | 129.31 Mn |
| Jun 30, 2025 | 124.58 Mn |
| Mar 31, 2025 | 121.09 Mn |
| Dec 31, 2024 | 118.68 Mn |
| Sep 30, 2024 | 106.87 Mn |
| Jun 30, 2024 | 93.90 Mn |
| Mar 31, 2024 | 94.06 Mn |
| Dec 31, 2023 | 100.51 Mn |
| Sep 30, 2023 | 107.01 Mn |
| Jun 30, 2023 | 107.32 Mn |
| Mar 31, 2023 | 107.97 Mn |
| Dec 31, 2022 | 112.85 Mn |
| Sep 30, 2022 | 117.16 Mn |
| Jun 30, 2022 | 124.05 Mn |
| Mar 31, 2022 | 132.65 Mn |
| Dec 31, 2021 | 139.97 Mn |
| Sep 30, 2021 | 144.51 Mn |
| Jun 30, 2021 | 140.63 Mn |